Stimulation of CD134 with an agonistic mAb enhanced the therapeutic efficacy of anti-CD20 treatment in a B-cell lymphoma mouse model and in an NK-dependent fashion. This evidence concerns the gene TNFRSF4 and B-cell non-Hodgkin lymphoma.